Prof. Jie Lu | Health Sciences | Best Scholar Award

Vice advisor, The Affiliated Hospital of Qingdao University, China

Dr. Jie Lu is a distinguished medical researcher and Associate Professor at The Affiliated Hospital of Qingdao University. With a strong background in internal medicine, endocrinology, and metabolism, Dr. Lu has made significant contributions to the field of hyperuricemia and gout research. His expertise in molecular and clinical studies has led to groundbreaking findings, including the development of a spontaneous hyperuricemia mouse model and critical insights into the relationship between hyperuricemia and metabolic disorders. His research has been widely recognized, earning him prestigious awards and global collaborations.

Publication Profile

Scopus
ORCID

🎓 Education

Dr. Jie Lu completed his MD and PhD in Internal Medicine from Qingdao University (2015-2018), following an MS in Endocrine and Metabolism (2012-2015) from the same institution. His academic journey began with a Bachelor’s in Medicine from Shandong Second Medical University (2007-2012), laying a strong foundation for his career in medical research.

👨‍🔬 Experience

Dr. Lu has been serving as an Associate Professor at The Affiliated Hospital of Qingdao University since 2022. Prior to this, he worked as a Research Fellow at the same institution (2018-2022), where he played a pivotal role in advancing hyperuricemia research. His international training experience spans institutions such as the University of Otago, Henry Ford Immunology Program in the USA, and the Chinese Academy of Sciences, enriching his expertise in bioinformatics, immunology, and molecular biology.

🏆 Awards and Honors

Dr. Lu’s excellence in medical research has been recognized through numerous prestigious awards. In 2022, he received the 13th Qingdao Youth Science and Technology Award. His contributions to scientific progress earned him the First Award of Shandong Province Science and Technology Progress in 2020. Throughout his academic career, he has been honored with multiple scholarships, including the National Graduate Scholarship (2017), Excellent Student Scholarship (2016-2017), and Freshman Scholarship (2015). His outstanding performance as a researcher and student has been acknowledged with multiple “Excellent Graduate” awards from Shandong Province and Qingdao University.

🔬 Research Focus

Dr. Lu’s research is dedicated to understanding the clinical and molecular mechanisms of hyperuricemia and gout. His pioneering work in constructing a spontaneous hyperuricemia mouse model has provided invaluable insights into disease progression and treatment strategies. His studies explore the relationship between hyperuricemia and renal function, diabetes, and arterial sclerosis, with high-impact publications in leading journals such as Nature Reviews Rheumatology, Kidney International, and Diabetes. He has also been instrumental in identifying the impact of COVID-19 vaccination on gout attacks, proposing colchicine as a preventive treatment.

🏁 Conclusion

Dr. Jie Lu is a leading researcher in hyperuricemia and gout, with a remarkable academic and research career. His extensive publications, international collaborations, and pioneering research have significantly contributed to the medical field. Recognized for his scientific achievements, Dr. Lu continues to make impactful discoveries that shape the future of metabolic disease treatment.

📚 Publications

Colchicine prophylaxis is associated with fewer gout flares after COVID-19 vaccination – Annals of the Rheumatic Diseases, 2022 🔗

Mouse models for human hyperuricaemia: a critical review – Nature Reviews Rheumatology, 2019 🔗

Knockout of the urate oxidase gene provides a stable mouse model of hyperuricemia associated with metabolic disorders – Kidney International, 2018 🔗

Hyperuricemia predisposes to the onset of diabetes via promoting pancreatic β-cell death in uricase-deficient male mice – Diabetes, 2020 🔗

Urate-lowering therapy alleviates atherosclerosis inflammatory response factors and neointimal lesions in a mouse model – The FEBS Journal, 2019 🔗

Superiority of low-dose benzbromarone to low-dose febuxostat in a prospective, randomized comparative effectiveness trial in gout patients with renal uric acid underexcretion – Arthritis Rheumatol, 2022 🔗

Metabolomics and Machine Learning Identify Metabolic Differences and Potential Biomarkers for Frequent Versus Infrequent Gout Flares – Arthritis Rheumatol, 2023 🔗

Profiling of Serum Oxylipins Identifies Distinct Spectrums and Potential Biomarkers in Young People with Very Early Onset Gout – Rheumatology (Oxford), 2023 🔗

Effects of fenofibrate therapy on renal function in primary gout patients – Rheumatology (Oxford), 2021 🔗

Trends in the manifestations of 9754 gout patients in a Chinese clinical center: A 10-year observational study – Joint Bone Spine, 2020 🔗

Dr. Doljinsuren Enkhbayar | Biomedical Engineering | Best Researcher Award

Ph.D candidate, Department of Biomedical Engineering, Yonsei University, South Korea

Doljinsuren Enkhbayar is a dedicated biomedical engineer specializing in AI-driven healthcare solutions and biomedical signal processing. Born in Ulaanbaatar, Mongolia, she has a strong background in medical equipment engineering and biomedical data science. With years of experience in both academic research and clinical applications, she is currently pursuing her Ph.D. in Biomedical Engineering at Yonsei University, South Korea. Her passion lies in wearable health technology, biosensors, and the integration of machine learning in medical diagnostics.

🎓 Education

Doljinsuren’s academic journey began at the Mongolian University of Science and Technology, where she earned a Bachelor of Engineering in Medical Equipment and Aircraft Maintenance Engineering. She further advanced her expertise with a Master of Science in Biomedical Engineering from the same university. Currently, she is a Ph.D. candidate at Yonsei University, South Korea, focusing on AI and machine learning applications in biomedical sciences.

💼 Experience

With a strong foundation in biomedical engineering, Doljinsuren has worked as a Biomedical Engineer at the National Center of Maternal and Child Health of Mongolia, where she specialized in medical equipment management and safety assessments. She later served as a Training Master in the Department of Electrotechnique at the Mongolian University of Science and Technology, contributing to research and mentoring students. Additionally, she played a pivotal role as a secretariat member of the Mongolian Society of Biomedical Engineering, advocating for technological advancements in healthcare.

🏆 Awards and Honors

Doljinsuren has received multiple accolades for her research excellence. She was awarded the Best Paper Award by the Mongolian Young Scientist Association (2022) for her study on electrosurgical unit output power measurement. She also gained international recognition for her work on predicting esophageal varices using platelet count/spleen size ratio, presented at Chulalongkorn University, Thailand (2020). Her research on chronic hepatitis C treatment was featured at Liver Week 2019 in Busan, Korea.

🔬 Research Focus

Her research interests revolve around AI in healthcare, biomedical signal processing, wearable health technologies, and biosensors. She actively explores how machine learning and biomedical data science can enhance diagnostics, patient monitoring, and medical device performance. Her contributions to biomaterials research, particularly chitosan-based sustainable packaging, reflect her interdisciplinary expertise in biomedical applications.

🔍 Conclusion

Doljinsuren Enkhbayar is a rising expert in biomedical engineering and AI-driven healthcare innovations. Her interdisciplinary research, coupled with her clinical and academic experience, positions her at the forefront of modern medical technology advancements. With an unwavering commitment to improving healthcare outcomes through AI and biomedical data science, she continues to push the boundaries of innovation and research excellence.

📚 Publications

Explainable Artificial Intelligence Models for Predicting Depression Based on Polysomnographic Phenotypes – Published in Bioengineering (2025). Read Here

Chitosan Extracted from the Biomass of Tenebrio molitor Larvae as a Sustainable Packaging Film – Published in Materials (2024). Read Here

Oral Administration of Hydrolysed Casein-Based Supplements on Chronic Liver Disease Patients – Published in The Liver Week (2020). Read Here

Significant Effect of Lifestyle Modification Intervention in Patients with Newly Diagnosed Type 2 Diabetes – Published in The Liver Week (2017). Read Here